StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.30−0.08 (-3.36%)

Close on Nov 13, 2026Market cap $109.82MP/E –Yield –

Minerva Neurosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Minerva Neurosciences's ebitda for the twelve months ending Dec 31, 2025 was -$15.10M. For fiscal 2025 it was -$15.10M. The highest annual figure on record is $1.86M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.10M–
FY2024Dec 31, 2024-$21.84M–
FY2023Dec 31, 2023-$23.11M-1340.9%
FY2020Dec 31, 2020$1.86M–
FY2019Dec 31, 2019-$75.85M–
FY2018Dec 31, 2018-$51.71M–
FY2017Dec 31, 2017-$41.16M–
FY2016Dec 31, 2016-$30.17M–
FY2015Dec 31, 2015-$26.09M–
FY2014Dec 31, 2014-$54.84M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$4.98M–
Q3 FY2025Sep 30, 2025-$2.84M–
Q2 FY2025Jun 30, 2025-$3.37M–
Q1 FY2025Mar 31, 2025-$3.90M–
Q4 FY2024Dec 31, 2024-$4.52M–
Q3 FY2024Sep 30, 2024-$4.37M–
Q2 FY2024Jun 30, 2024-$6.28M–
Q1 FY2024Mar 31, 2024-$6.68M–
Q4 FY2023Dec 31, 2023-$7.17M–
Q3 FY2023Sep 30, 2023-$6.08M–
Q2 FY2023Jun 30, 2023-$4.52M-115.3%
Q1 FY2023Mar 31, 2023-$5.35M–
Q4 FY2020Dec 31, 2020-$7.30M–
Q3 FY2020Sep 30, 2020-$8.09M–
Q2 FY2020Jun 30, 2020$29.51M–
Q1 FY2020Mar 31, 2020-$12.27M–
Q4 FY2019Dec 31, 2019-$32.36M–
Q3 FY2019Sep 30, 2019-$14.28M–
Q2 FY2019Jun 30, 2019-$12.90M–
Q1 FY2019Mar 31, 2019-$16.31M–
Q4 FY2018Dec 31, 2018-$13.62M–
Q3 FY2018Sep 30, 2018-$12.42M–
Q2 FY2018Jun 30, 2018-$12.93M–
Q1 FY2018Mar 31, 2018-$12.74M–
Q4 FY2017Dec 31, 2017-$9.53M–
Q3 FY2017Sep 30, 2017-$11.40M–
Q2 FY2017Jun 30, 2017-$9.74M–
Q1 FY2017Mar 31, 2017-$10.48M–
Q4 FY2016Dec 31, 2016-$9.23M–

More Minerva Neurosciences figures

See a number that looks wrong?